Allocation of Resources between Smoking Cessation Methods and Lovastatin Treatment of Hypercholesterolaemia: Based on Cost Effectiveness and the Social Welfare Function

PharmacoEconomics

Volumn 22, Issue 1, 2004, Pages 55-69

  Plans Rubió, Pedro ^a,b  

^a Evaluation Unit   (Spain)

^b Evaluation Unit   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CHOLESTEROL; COLESTYRAMINE; FLUINDOSTATIN; GEMFIBROZIL; MEVINOLIN; NICOTINE DERIVATIVE; NICOTINE GUM; PRAVASTATIN; SIMVASTATIN;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; COST EFFECTIVENESS ANALYSIS; DRUG COST; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; LOGISTIC REGRESSION ANALYSIS; MALE; MULTIPLE REGRESSION; PRIMARY PREVENTION; PRIORITY JOURNAL; RESOURCE ALLOCATION; SMOKING CESSATION; SOCIAL WELFARE; SPAIN; TOBACCO DEPENDENCE; TRANSDERMAL PATCH;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, ORAL; ALGORITHMS; ANTICHOLESTEREMIC AGENTS; COST-BENEFIT ANALYSIS; FEMALE; HEALTH CARE RATIONING; HUMANS; HYPERCHOLESTEROLEMIA; LOVASTATIN; MALE; NICOTINE; SMOKING CESSATION; SOCIAL WELFARE; SOCIOECONOMIC FACTORS; SPAIN;

EID: 0442291753     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200422010-00005     Document Type: Article

References (35)

1. Gold MR, Siegel JE, Russell LB, et al., editors. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996
2. Weinstein MC. Principles of cost-effectiveness resource allocation in health care organizations. Int J Technol Assess Health Care 1990; 6: 93-103
3. Cuyler AJ. The normative economics of health care finance and provision. Oxford Rev Econ Policy 1989; 5: 34-58
4. Wagstaff A. QALY and the equity-efficiency trade-off. J Health Econ 1991; 10: 21-41
5. Birch S, Gafni A. Cost-effectiveness/utility analysis: do current decision rules lead us to where we want to be? J Health Econ 1972; 11: 279-96
6. Le Grand J. The strategy of equality. London: Allen & Unwin. 1982
7. Cuyler AJ, Wagstaff A. Equity and equality in health and health care. J Health Econ 1993; 12: 431-57
8. Dolan P. The measurement of individual utility and social welfare. J Health Econ 1998; 17: 39-52
9. Nord E, Richardson J, Street A, et al. Maximizing health benefits vs egalitarianism: an Australian survey of health issues. Soc Sci Med 1995; 41: 1429-37
10. National Cholesterol Education Program. Second report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). Circulation 1994; 89: 1333-45
11. National Cholesterol Education Program. Executive summary of the third report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-97
12. Ministerio de Sanidad y Consumo, Sociedad Española de Cardiología y Sociedad Española de Arteriosclerosis. Control de la Colesterolemia en España, 2000. Instrumento para la prevención cardiovascular (Hypercholesterolemia control in Spain, 2000. Instrument for cardiovascular prevention). Clin Invest Arteriosclerosis 2000; 12: 125-52
13. Tang JL, Law M, Wald N. How effective is nicotine replacement therapy in helping people to stop smoking? BMJ 1994; 308: 21-6
14. Plans-Rubió P. Cost-effectiveness analysis of treatments to reduce cholesterol levels, blood pressure and smoking for the prevention of coronary heart disease: evaluative study carried out in Spain. Pharmacoeconomics 1998; 13 (5 Pt 2): 623-43
15. Henningfield JE. Nicotine medications for smoking cessation. N Engl J Med 1995; 333: 1196-203
16. Lancaster T, Stead L, Silagy C, for the Tobacco Addiction Review Group, et al. Effectiveness of interventions to help people stop smoking: findings from the Cochrane Library. BMJ 2000; 321: 355-8
17. Ministerio de Sanidad. Consenso para el control de la colesterolemia en España (Consensus for the control of hypercholesterolemia in Spain). Clin Invest Arteriosclerosis 1989; 1: 55-61
18. Grover SA, Abrahamowicz M, Joseph L, et al. The benefits of treating hyperlipidemia to prevent coronary heart disease: estimating changes in life expectancy and morbidity. JAMA 1992; 267: 816-22
19. Glick H, Hayse JF, Thomson D, et al. A model for evaluating the cost-effectiveness of cholesterol-lowering treatment. Philadelphia (PA): Leonard Davis Institute of Health Economics, University of Pennsylvania, 1990
20. Wilson PWF, D'Agostino RB, Levy D, et al. Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97: 1837-47
21. Plans P, Pardell H, Salleras L. Epidemiology of cardiovascular disease risk factors in Catalonia (Spain). Eur J Epidemiol 1993; 9: 381-9
22. Plans P, Ruigómez J, Pardell H, et al. Distributión de lípidos en la población adulta de Cataluña (Distribution of lipids in the adult population of Catalonia). Rev Clin Esp 1993; 193: 35-42
23. Norusis NJ. SPSS advanced statistics. Chicago (IL): SPSS Inc., 1988
24. Hosmer DW, Lemeshow S. Applied logistic regression. New York (NY): Wiley, 1989
25. Greenberg RS, Kleinbaum DG. Mathematical modeling strategies for the analysis of epidemiologic research. Annu Rev Public Health 1985; 6: 223-45
26. Plans-Rubió P. Cost-effectiveness of cardiovascular prevention programs in Spain. Int J Technol Assess Health Care 1998; 14: 320-30
27. Van Doorslaer E, Wagstaff A, Rutten F, editors. Equity in the finance and delivery of health care: an international perspective. Oxford: Oxford University Press, 1993
28. Human Development Report. United Nations Development Programme. Oxford: Oxford University Press, 1995
29. Johannesson M, Gerdtham U-G. A note on the estimation of the equity-efficiency trade-off for QALYs. J Health Econ 1996; 15: 359-68
30. Anderson F, Lyttkens CH. Preferences for equity in health behind a veil of ignorance. Health Econ 1999; 8: 369-78
31. Lindholm L, Rosén M. On the measurement of the nation's equity adjusted health. Health Econ 1998; 7: 621-8
32. Kaplow L, Shadell S. Notions of fairness versus the Pareto principle: on the role of logical consistency. Yale Law J 2000; 110: 237-49
33. Plans-Rubió P. Management of pharmaceutical resources for the primary prevention of coronary heart disease in Catalonia (Spain) based on efficiency and equity. Dis Manage Health Outcomes 2001; 9: 495-506
34. Eddy DM. Oregon's methods: did cost-effectiveness analysis fail? JAMA 1991; 266: 2135-41
35. Hadorn DC. Setting health care priorities in Oregon: cost-effectiveness meets the rule of rescue. JAMA 1991; 265: 2218-25